Physician profile
Paul E Gerard
NPI 1154327385
$4,527.76
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $667 · 2021: $1,079 · 2022: $873 · 2023: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $818.83 | 2019-2023 | Wegovy |
| Lilly USA, LLC | $494.69 | 2019-2023 | Mounjaro |
| Pfizer INC. | $428.31 | 2019-2023 | |
| Abbvie INC. | $347.59 | 2021-2023 | |
| Glaxosmithkline, LLC. | $295.62 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $275.73 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.29 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $181.77 | 2021 | |
| Allergan, INC. | $175.29 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.00 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $151.25 | 2022 | |
| Merck Sharp & Dohme LLC | $110.78 | 2019-2023 | Dificid, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $96.35 | 2019-2023 | Spravato |
| Esperion Therapeutics, INC. | $74.53 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $73.49 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $71.36 | 2019-2023 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.05 | 2019-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $49.21 | 2022-2023 | |
| Astellas Pharma US INC | $47.97 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $44.94 | 2023 | Rexulti |
| Exact Sciences Corporation | $40.13 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $38.76 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $36.20 | 2023 | Quviviq |
| Amarin Pharma, INC. | $31.17 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $27.35 | 2019-2023 | |
| Eisai INC. | $24.54 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $24.45 | 2020 | |
| Sunovion Pharmaceuticals INC. | $21.32 | 2022 | |
| Abbott Laboratories | $19.13 | 2021 | |
| Axsome Therapeutics, INC. | $18.65 | 2023 | Auvelity |
| Inogen, INC. | $17.06 | 2022 | |
| Sumitomo Pharma America, INC. | $15.81 | 2023 | Gemtesa |
| Dexcom, INC. | $12.77 | 2021 | |
| Genentech USA, INC. | $12.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gerard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.